Synergistic Anticancer Effects of Polyphyllin I and Evodiamine on Freshly-Removed Human Gastric Tumors

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Yue, Guofeng ^a   Wei, Jia ^a,b   Qian, Xiaoping ^a,b   Yu, Lixia ^a,b   Zou, Zhengyun ^a,b   Guan, Wenxian ^b   Wang, Hao ^b   Shen, Jie ^a,b   Liu, Baorui ^a,b  

^a THE AFFILIATED DRUM TOWER HOSPITAL OF NANJING UNIVERSITY MEDICAL SCHOOL   (China)

^b MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE; EVODIAMINE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; IRINOTECAN; PLATINUM COMPLEX; POLYPHYLLIN 1; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG;

ADULT; ANTINEOPLASTIC ACTIVITY; APRATAXIN GENE; ARTICLE; CONTROLLED STUDY; DNA TOPOISOMERASE GENE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG STRUCTURE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1 GENE; FEMALE; GENE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER; THYMIDYLATE SYNTHASE GENE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CONFIDENCE INTERVALS; DIOSGENIN; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; FEMALE; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PLATINUM; QUINAZOLINES; RNA, MESSENGER; STOMACH NEOPLASMS;

EID: 84878765717     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0065164     Document Type: Article

References (33)

1. Jemal A, Bray F, (2011) Center MM, Ferlay J, Ward E, et al (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, et al. (2006) Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 24: 2903-2909.
3. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, et al. (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358: 36-46.
4. Kong M, Fan J, Dong A, Cheng H, Xu R, (2010) Effects of polyphyllin I on growth inhibition of human non-small lung cancer cells and in xenograft. Acta Biochim Biophys Sin (Shanghai) 42: 827-833.
5. Lee MS, Yuet-Wa JC, Kong SK, Yu B, Eng-Choon VO, et al. (2005) Effects of polyphyllin D, a steroidal saponin in Paris polyphylla, in growth inhibition of human breast cancer cells and in xenograft. Cancer Biol Ther 4: 1248-1254.
6. Ong RC, Lei J, Lee RK, Cheung JY, Fung KP, et al. (2008) Polyphyllin D induces mitochondrial fragmentation and acts directly on the mitochondria to induce apoptosis in drug-resistant HepG2 cells. Cancer Lett 261: 158-164.
7. Sun J, Liu BR, Hu WJ, Yu LX, Qian XP, (2007) In vitro anticancer activity of aqueous extracts and ethanol extracts of fifteen traditional Chinese medicines on human digestive tumor cell lines. Phytother Res 21: 1102-1104.
8. Pan X, Hartley JM, Hartley JA, White KN, Wang Z, et al. (2012) Evodiamine, a dual catalytic inhibitor of type I and II topoisomerases, exhibits enhanced inhibition against camptothecin resistant cells. Phytomedicine 19: 618-624.
9. Adams M, Mahringer A, Kunert O, Fricker G, Efferth T, et al. (2007) Cytotoxicity and p-glycoprotein modulating effects of quinolones and indoloquinazolines from the Chinese herb Evodia rutaecarpa. Planta Med 73: 1554-1557.
10. Huang DM, Guh JH, Huang YT, Chueh SC, Chiang PC, et al. (2005) Induction of mitotic arrest and apoptosis in human prostate cancer pc-3 cells by evodiamine. J Urol 173: 256-261.
11. Chan AL, Chang WS, Chen LM, Lee CM, Chen CE, et al. (2009) Evodiamine stabilizes topoisomerase I-DNA cleavable complex to inhibit topoisomerase I activity. Molecules 14: 1342-1352.
12. Zhang Y, Wu LJ, Tashiro S, Onodera S, Ikejima T, (2003) Intracellular regulation of evodiamine-induced A375-S2 cell death. Biol Pharm Bull 26: 1543-1547.
13. Zhang Y, Zhang QH, Wu LJ, Tashiro S, Onodera S, et al. (2004) Atypical apoptosis in L929 cells induced by evodiamine isolated from Evodia rutaecarpa. J Asian Nat Prod Res 6: 19-27.
14. Huang YC, Guh JH, Teng CM, (2004) Induction of mitotic arrest and apoptosis by evodiamine in human leukemic T-lymphocytes. Life Sci 75: 35-49.
15. Shen J, Wang H, Wei J, Yu L, Xie L, et al. (2012) Thymidylate synthase mRNA levels in plasma and tumor as potential predictive biomarkers for raltitrexed sensitivity in gastric cancer. Int J Cancer 131: E938-945.
16. Fujita Y, Hiramatsu M, Kawai M, Nishimura H, Miyamoto A, et al. (2009) Histoculture drug response assay predicts the postoperative prognosis of patients with esophageal cancer. Oncol Rep 21: 499-505.
17. Chou TC, (2010) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70: 440-446.
18. Wei J, Costa C, Ding Y, Zou Z, Yu L, et al. (2011) mRNA expression of BRCA1, PIAS1, and PIAS4 and survival after second-line docetaxel in advanced gastric cancer. J Natl Cancer Inst 103: 1552-1556.
19. Margeli M, Cirauqui B, Castella E, Tapia G, Costa C, et al. (2010) The prognostic value of BRCA1 mRNA expression levels following neoadjuvant chemotherapy in breast cancer. PLoS One 5: e9499.
20. Livak KJ, Schmittgen TD, (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
21. Wei J, Zou Z, Qian X, Ding Y, Xie L, et al. (2008) ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen. Br J Cancer 98: 1398-1402.
22. Rosell R, Felip E, Taron M, Majo J, Mendez P, et al. (2004) Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery. Clin Cancer Res 10: 4215s-4219s.
23. Cecere F, Bria E, Rosell R (2006) DNA repair by ERCC1 in non-small-cell lung cancer. N Engl J Med 355: 2590-2591; author reply 2591.
24. Bathe OF, Franceschi D, Livingstone AS, Moffat FL, Tian E, et al. (1999) Increased thymidylate synthase gene expression in liver metastases from colorectal carcinoma: implications for chemotherapeutic options and survival. Cancer J Sci Am 5: 34-40.
25. Cascinu S, Aschele C, Barni S, Debernardis D, Baldo C, et al. (1999) Thymidylate synthase protein expression in advanced colon cancer: correlation with the site of metastasis and the clinical response to leucovorin-modulated bolus 5-fluorouracil. Clin Cancer Res 5: 1996-1999.
26. Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, et al. (1995) Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 55: 1407-1412.
27. Lenz HJ, Leichman CG, Danenberg KD, Danenberg PV, Groshen S, et al. (1996) Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol 14: 176-182.
28. Dopeso H, Mateo-Lozano S, Elez E, Landolfi S, Ramos Pascual FJ, et al. (2010) Aprataxin tumor levels predict response of colorectal cancer patients to irinotecan-based treatment. Clin Cancer Res 16: 2375-2382.
29. Furukawa T, Kubota T, Hoffman RM, (1995) Clinical applications of the histoculture drug response assay. Clin Cancer Res 1: 305-311.
30. Miller BE, Miller FR, Heppner GH (1984) Assessing tumor drug sensitivity by a new in vitro assay which preserves tumor heterogeneity and subpopulation interactions. J Cell Physiol Suppl 3: 105-116.
31. Tanino H, Oura S, Hoffman RM, Kubota T, Furukawa T, et al. (2001) Acquisition of multidrug resistance in recurrent breast cancer demonstrated by the histoculture drug response assay. Anticancer Res 21: 4083-4086.
32. Ariyoshi Y, Shimahara M, Tanigawa N, (2003) Study on chemosensitivity of oral squamous cell carcinomas by histoculture drug response assay. Oral Oncol 39: 701-707.
33. Hasegawa Y, Goto M, Hanai N, Ijichi K, Adachi M, et al. (2007) Evaluation of optimal drug concentration in histoculture drug response assay in association with clinical efficacy for head and neck cancer. Oral Oncol 43: 749-756.